The Association of HPV Vaccination and Risk of Immune-Mediated Diseases.

IF 6.4 4区医学 Q1 MEDICINE, GENERAL & INTERNAL

QJM: An International Journal of Medicine Pub Date : 2025-08-07 DOI:10.1093/qjmed/hcaf154

Qianru Zhang, Renin Chang, James Cheng-Chung Wei, Shiow-Ing Wang, Yao-Min Hung

{"title":"The Association of HPV Vaccination and Risk of Immune-Mediated Diseases.","authors":"Qianru Zhang, Renin Chang, James Cheng-Chung Wei, Shiow-Ing Wang, Yao-Min Hung","doi":"10.1093/qjmed/hcaf154","DOIUrl":null,"url":null,"abstract":"Background: Whether prior human papillomavirus vaccination (HPVV) can influence later development of immune-mediated diseases remain controversial. We aim to examine HPVV 's association with various immune-mediated diseases among females aged 9-45 years, considering age, vaccine types, and racial disparities.Methods: Based on data from the US Collaborative Network in TriNetX spanning from January 1, 2018, to December 20, 2022, we enrolled 208,638 females aged 9-45 years who had received HPVV and matched them with 208,638 individuals who had never received HPVV, using propensity scores. The primary outcome was the incidence of immune-mediated diseases. We conducted Cox proportional hazard regression analyses to estimate hazard ratios (HR) and 95% confidence intervals (CI). Subgroup analyses were conducted, stratified by age, race, smoking, obesity, asthma, and different types of HPV vaccines. Additionally, we executed sensitivity analyses to evaluate the robustness of our findings.Result: HPVV was associated with reduced risks of rheumatoid arthritis (HR: 0.487, 95% CI: 0.311 to 0.762), systemic lupus erythematosus (HR: 0.287, 95% CI: 0.179 to 0.460), dermatomyositis (HR: 0.299, 95% CI: 0.098 to 0.908), inflammatory bowel disease (HR: 0.876, 95% CI: 0.811 to 0.946), celiac disease (HR: 0.400, 95% CI: 0.304 to 0.526), and type 1 diabetes mellitus (HR: 0.242, 95% CI: 0.184 to 0.318). Subgroup analyses indicated a significant reduction in the incidence of immune-mediated diseases among females aged 9-26 years and those who had received the 9-valent HPV vaccines, compared to unvaccinated populations.Conclusion: This study indicates HPVV is associated with reduced risks of various immune-mediated diseases.","PeriodicalId":20806,"journal":{"name":"QJM: An International Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":6.4000,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"QJM: An International Journal of Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/qjmed/hcaf154","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Whether prior human papillomavirus vaccination (HPVV) can influence later development of immune-mediated diseases remain controversial. We aim to examine HPVV 's association with various immune-mediated diseases among females aged 9-45 years, considering age, vaccine types, and racial disparities.

Methods: Based on data from the US Collaborative Network in TriNetX spanning from January 1, 2018, to December 20, 2022, we enrolled 208,638 females aged 9-45 years who had received HPVV and matched them with 208,638 individuals who had never received HPVV, using propensity scores. The primary outcome was the incidence of immune-mediated diseases. We conducted Cox proportional hazard regression analyses to estimate hazard ratios (HR) and 95% confidence intervals (CI). Subgroup analyses were conducted, stratified by age, race, smoking, obesity, asthma, and different types of HPV vaccines. Additionally, we executed sensitivity analyses to evaluate the robustness of our findings.

Result: HPVV was associated with reduced risks of rheumatoid arthritis (HR: 0.487, 95% CI: 0.311 to 0.762), systemic lupus erythematosus (HR: 0.287, 95% CI: 0.179 to 0.460), dermatomyositis (HR: 0.299, 95% CI: 0.098 to 0.908), inflammatory bowel disease (HR: 0.876, 95% CI: 0.811 to 0.946), celiac disease (HR: 0.400, 95% CI: 0.304 to 0.526), and type 1 diabetes mellitus (HR: 0.242, 95% CI: 0.184 to 0.318). Subgroup analyses indicated a significant reduction in the incidence of immune-mediated diseases among females aged 9-26 years and those who had received the 9-valent HPV vaccines, compared to unvaccinated populations.

Conclusion: This study indicates HPVV is associated with reduced risks of various immune-mediated diseases.

查看原文本刊更多论文

HPV疫苗接种与免疫介导疾病风险的关系。

背景：先前的人乳头瘤病毒疫苗接种（HPVV）是否会影响免疫介导性疾病的后期发展仍然存在争议。我们的目的是在考虑年龄、疫苗类型和种族差异的情况下，研究9-45岁女性中hpv与各种免疫介导疾病的关系。方法：基于美国TriNetX合作网络2018年1月1日至2022年12月20日的数据，我们招募了208,638名年龄在9-45岁之间接受过HPVV的女性，并使用倾向评分将其与从未接受过HPVV的208,638名个体进行匹配。主要终点是免疫介导性疾病的发生率。我们进行了Cox比例风险回归分析来估计风险比（HR）和95%置信区间（CI）。进行亚组分析，按年龄、种族、吸烟、肥胖、哮喘和不同类型的HPV疫苗进行分层。此外，我们还进行了敏感性分析，以评估研究结果的稳健性。结果：HPVV与类风湿关节炎（HR: 0.487, 95% CI: 0.311 ~ 0.762）、系统性红斑狼疮（HR: 0.287, 95% CI: 0.179 ~ 0.460）、皮肌炎（HR: 0.299, 95% CI: 0.098 ~ 0.908）、炎症性肠病（HR: 0.876, 95% CI: 0.811 ~ 0.946）、乳糜泻（HR: 0.400, 95% CI: 0.304 ~ 0.526）和1型糖尿病（HR: 0.242, 95% CI: 0.184 ~ 0.318）的风险降低相关。亚组分析表明，与未接种疫苗的人群相比，9-26岁女性和接种9价HPV疫苗的人群中免疫介导疾病的发病率显著降低。结论：本研究表明HPVV与各种免疫介导疾病的风险降低有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

QJM: An International Journal of Medicine 医学-医学：内科

CiteScore

6.90

自引率

5.30%

发文量

263

审稿时长

4-8 weeks

期刊介绍： QJM, a renowned and reputable general medical journal, has been a prominent source of knowledge in the field of internal medicine. With a steadfast commitment to advancing medical science and practice, it features a selection of rigorously reviewed articles. Released on a monthly basis, QJM encompasses a wide range of article types. These include original papers that contribute innovative research, editorials that offer expert opinions, and reviews that provide comprehensive analyses of specific topics. The journal also presents commentary papers aimed at initiating discussions on controversial subjects and allocates a dedicated section for reader correspondence. In summary, QJM's reputable standing stems from its enduring presence in the medical community, consistent publication schedule, and diverse range of content designed to inform and engage readers.